Sign in or create an account to add this stock to your watchlist.
About Onyx Pharmaceuticals (NASDAQ:ONXX)
Onyx Pharmaceuticals, Inc. (Onyx) is a biopharmaceutical company. The Company is developing therapies that target the molecular mechanisms that cause cancer. The Company has built two franchise platforms: one in kinase inhibition and one in proteasome inhibition. In its kinase inhibitor franchise, its product, Nexavar (sorafenib) tablets is approved for unresectable liver cancer and advanced kidney cancer. unresectable liver cancer and advanced kidney cancer. With its development and marketing partner Bayer HealthCare Pharmaceuticals Inc., or Bayer, the Company shares equally in the profits and losses of Nexavar worldwide except Japan. A kinase inhibitor, regorafenib, is an investigational agent that has already demonstrated positive Phase 3 survival data in metastatic colorectal cancer, and is being evaluated in a Phase 3 study in gastrointestinal stromal tumors (GIST).
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on AssetsN/A
Onyx Pharmaceuticals (NASDAQ:ONXX) Frequently Asked Questions
What is Onyx Pharmaceuticals' stock symbol?
Onyx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ONXX."
Has Onyx Pharmaceuticals been receiving favorable news coverage?
News articles about ONXX stock have trended somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Onyx Pharmaceuticals earned a news sentiment score of 0.13 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 46.77 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
How do I buy shares of Onyx Pharmaceuticals?
Shares of ONXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Onyx Pharmaceuticals?
Onyx Pharmaceuticals' mailing address is 249 E Grand Ave, SOUTH SAN FRANCISCO, CA 94080-4804, United States. The biopharmaceutical company can be reached via phone at +1-650-2660000.
MarketBeat Community Rating for Onyx Pharmaceuticals (ONXX)MarketBeat's community ratings are surveys of what our community members think about Onyx Pharmaceuticals and other stocks. Vote "Outperform" if you believe ONXX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONXX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Onyx Pharmaceuticals (NASDAQ:ONXX) Analyst Ratings History
(Data available from 5/27/2016 forward)
|Date||Brokerage||Action||Rating||Price Target||Impact on Share Price||Details|
Onyx Pharmaceuticals (NASDAQ:ONXX) Earnings History and Estimates Chart
Onyx Pharmaceuticals (NASDAQ ONXX) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/8/2013||Q2 2013||($0.42)||($0.40)||$151.73 million||$153.00 million||View||N/A|
|5/7/2013||Q1 2013||($0.47)||($0.19)||$134.36 million||$145.50 million||View||N/A|
|2/21/2013||Q4 2012||($0.76)||($0.36)||$113.17 million||$127.90 million||View||N/A|
|11/1/2012||Q312||($0.95)||($0.79)||$80.02 million||$89.51 million||View||N/A|
Onyx Pharmaceuticals (NASDAQ:ONXX) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Onyx Pharmaceuticals (NASDAQ ONXX) Insider Trading and Institutional Ownership History
Onyx Pharmaceuticals (NASDAQ ONXX) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|8/12/2013||Helen Torley||EVP||Sell||9,311||$126.89||$1,181,472.79||46,585|| |
|8/8/2013||Matthew Fust||CFO||Sell||2,492||$128.21||$319,499.32||40,303|| |
|8/7/2013||Suzanne Shema||EVP||Sell||4,052||$131.86||$534,296.72||34,618|| |
|8/6/2013||Kaye Foster-Cheek||SVP||Sell||8,878||$132.81||$1,179,087.18||27,066|| |
|7/30/2013||Corinne H Nevinny||Director||Sell||1,500||$131.26||$196,890.00|| |
|7/26/2013||Lopez Antonio J Grillo||Director||Sell||2,000||$130.50||$261,000.00|| |
|7/26/2013||Matthew K Fust||CFO||Sell||6,043||$130.50||$788,611.50|| |
|7/8/2013||Suzanne M Shema||EVP||Sell||4,052||$135.76||$550,099.52|| |
|7/2/2013||Matthew K Fust||CFO||Sell||1,551||$132.80||$205,972.80|| |
|7/1/2013||Juergen Lasowski||EVP||Sell||25,375||$132.63||$3,365,486.25|| |
|7/1/2013||Julianna R Wood||VP||Sell||2,304||$132.63||$305,579.52|| |
|7/1/2013||Paul Goddard||Director||Sell||6,000||$132.21||$793,260.00|| |
|6/19/2013||Corinne H Nevinny||Director||Sell||1,000||$88.25||$88,250.00|| |
|6/10/2013||Julianna R Wood||VP||Sell||2,306||$92.30||$212,843.80|| |
|6/7/2013||Suzanne M Shema||EVP||Sell||4,052||$91.23||$369,663.96|| |
|6/5/2013||N Anthony Coles||CEO||Sell||6,562||$90.00||$590,580.00|| |
|5/14/2013||Juergen Lasowski||EVP||Sell||4,182||$96.60||$403,981.20|| |
|5/13/2013||Helen Torley||EVP||Sell||8,250||$98.13||$809,572.50|| |
|5/13/2013||Matthew K Fust||CFO||Sell||10,269||$98.22||$1,008,621.18|| |
|4/11/2013||Lopez Antonio J Grillo||Director||Sell||43,164||$96.73||$4,175,253.72|| |
|4/10/2013||Julianna R Wood||VP||Sell||9,948||$95.00||$945,060.00|| |
|4/10/2013||Paul Goddard||Director||Sell||2,000||$95.00||$190,000.00|| |
|3/11/2013||Julianna R Wood||VP||Sell||3,331||$85.65||$285,300.15|| |
|3/11/2013||Magnus Lundberg||Director||Sell||5,000||$88.00||$440,000.00|| |
|10/5/2012||Juergen Lasowski||EVP||Sell||5,902||$90.00||$531,180.00|| |
|10/4/2012||Helen Torley||EVP||Sell||2,314||$86.51||$200,184.14|| |
|10/2/2012||Kaye I Foster-Cheek||SVP||Sell||2,015||$85.08||$171,436.20|| |
Onyx Pharmaceuticals (NASDAQ ONXX) News Headlines
Onyx Pharmaceuticals (NASDAQ:ONXX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Onyx Pharmaceuticals (NASDAQ:ONXX) Income Statement, Balance Sheet and Cash Flow Statement
Onyx Pharmaceuticals (NASDAQ ONXX) Stock Chart for Sunday, May, 27, 2018